Medtronic Addresses Diabetes Care Disparities With New Equity Initiatives

The company announced new research investments and partnerships with the American Diabetes Association and the T1D Exchange to address racial disparities in treatment of diabetes.

Finding balance, equality, stability concept with libra, scale, balls or globes in realistic studio interior room, 3d rendering illustration wallpaper - Image ID: 2CFHT2P
• Source: Alany

Medtronic is taking advantage of its vast resources and network of relationships with health care providers to improve access to diabetes care in underserved communities.

"Underlying barriers to health equity – including awareness, access, trust, bias and affordability – are unfortunate truths that exist in the US health care system," said Sean Salmon, president of Medtronic's diabetes business

More from Diabetic Care

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

Roche To Localize CGM Manufacturing in US with $550M Indiana Site Investment

 
• By 

Roche’s Indianapolis site currently produces 5.2 billion Accu-Chek test strips annually and supports distribution to 53 countries. The new CGM line will add to an already diversified operational footprint, which includes R&D, laboratories, manufacturing, and IT services.

Consumer Healthtech Investment Totaled $4.5BN In 2024, But Bar Is High Amid Economic Uncertainty

 
• By 

Global investment in consumer healthtech increased by 9% year-over-year in 2024, totaling $4.5bn, with significant interest in mental health solutions, according to Galen Growth. While the first quarter of 2025 saw raised confidence and investments, the Trump administration’s new tariffs and sweeping changes to healthcare have introduced new uncertainties.

Dexcom Puts Stelo On Amazon, Setting Up Consumer Showdown With Abbott

 
• By 

In addition to broader distribution, Dexcom is investing heavily in software enhancements for Stelo. The 180-day data lookback feature is just one of several planned upgrades intended to improve personalization and user engagement.

More from Device Area